WO2004070008A3 - Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors - Google Patents

Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors Download PDF

Info

Publication number
WO2004070008A3
WO2004070008A3 PCT/US2004/002609 US2004002609W WO2004070008A3 WO 2004070008 A3 WO2004070008 A3 WO 2004070008A3 US 2004002609 W US2004002609 W US 2004002609W WO 2004070008 A3 WO2004070008 A3 WO 2004070008A3
Authority
WO
WIPO (PCT)
Prior art keywords
telomerase
compositions
methods
suramin
antisense
Prior art date
Application number
PCT/US2004/002609
Other languages
French (fr)
Other versions
WO2004070008A2 (en
WO2004070008A8 (en
Inventor
Jessie L-S Au
M Guillaume Wientjes
Original Assignee
Jessie L-S Au
M Guillaume Wientjes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jessie L-S Au, M Guillaume Wientjes filed Critical Jessie L-S Au
Priority to EP04706977A priority Critical patent/EP1606302A4/en
Priority to JP2006503176A priority patent/JP2007525414A/en
Priority to CA002515000A priority patent/CA2515000A1/en
Priority to AU2004209428A priority patent/AU2004209428A1/en
Publication of WO2004070008A2 publication Critical patent/WO2004070008A2/en
Publication of WO2004070008A3 publication Critical patent/WO2004070008A3/en
Priority to US11/193,883 priority patent/US20050282893A1/en
Publication of WO2004070008A8 publication Critical patent/WO2004070008A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods and compositions for inhibiting telomerase activity and treatment of telomerase mediated conditions or diseases. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents, surgery, or radiation in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer.
PCT/US2004/002609 2003-01-31 2004-01-30 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors WO2004070008A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04706977A EP1606302A4 (en) 2003-01-31 2004-01-30 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
JP2006503176A JP2007525414A (en) 2003-01-31 2004-01-30 Methods and ingredients for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CA002515000A CA2515000A1 (en) 2003-01-31 2004-01-30 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
AU2004209428A AU2004209428A1 (en) 2003-01-31 2004-01-30 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
US11/193,883 US20050282893A1 (en) 2004-01-30 2005-07-29 Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44406103P 2003-01-31 2003-01-31
US60/444,061 2003-01-31

Publications (3)

Publication Number Publication Date
WO2004070008A2 WO2004070008A2 (en) 2004-08-19
WO2004070008A3 true WO2004070008A3 (en) 2005-05-26
WO2004070008A8 WO2004070008A8 (en) 2005-09-29

Family

ID=32850822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002609 WO2004070008A2 (en) 2003-01-31 2004-01-30 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors

Country Status (6)

Country Link
EP (1) EP1606302A4 (en)
JP (1) JP2007525414A (en)
CN (1) CN1768075A (en)
AU (1) AU2004209428A1 (en)
CA (1) CA2515000A1 (en)
WO (1) WO2004070008A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456333B8 (en) * 2012-12-07 2020-05-13 Geron Corporation Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
AU2017376817B2 (en) 2016-12-13 2022-03-31 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018107226A1 (en) * 2016-12-13 2018-06-21 Beta Therapeutics Pty. Ltd. Methods of treating ocular disorders
JPWO2022114111A1 (en) * 2020-11-27 2022-06-02

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BRANCH A.D. ET AL: "A good antisense molecule is hard to find", TIBS, vol. 23, 2000, pages 45 - 50, XP004108000 *
CHIANG ET L.: "Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis", JOURNAL OF UROLOGY, vol. 164, December 2000 (2000-12-01), pages 2119 - 2125, XP005554234 *
CROOKE ET AL.: "Basic principles of antisense therapeutics", 1998, pages: 1 - 50, XP000900999 *
DAMM ET AL.: "A highly selective telomerase inhibitor limiting human cancer cell proliferation", EMBO JOURNAL 20, 2001, pages 6958 - 6968, XP008102737 *
DRUCKER ET AL.: "Thalidomide down-regulates transcript levels of GC-ritch promoter genes in multiple myeloma", MOL. PHARMACOLOGY, vol. 64, no. 2, 9 May 2003 (2003-05-09), pages 415 - 420, XP008102917 *
GOWEN ET AL.: "A G-quadraplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity", MOLECULAR PHARMACOLOGY, vol. 61, no. 5, 6 February 2002 (2002-02-06), pages 1154 - 1162, XP002982410 *
GREEN D.W. ET AL: "Antisense oligonucleotides: an evolving technology for the modulation of gene expression", HUMAN DISEASES, vol. 191, 2000, pages 93 - 105, XP002948604 *
JEN ET AL.: "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies", STEM CELLS, vol. 18, 2000, pages 307 - 319, XP002181426 *
KOMATA ET AL.: "Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53", GENE THERAPY, vol. 7, August 2000 (2000-08-01), pages 2071 - 2079, XP002965377 *
MEYERS ET AL.: "Suramin analogs inhibit human angiodenesis in vitro", J. SURG. RESEARCH, vol. 91, 2002, pages 130 - 134, XP008102508 *
PERRY ET AL.: "Recent advances in the development of telomerase inhibitors for the treatment of cancer", EXP. OPIN. INVEST. DRUGS, vol. 8, 1999, pages 1981 - 2008, XP009000752 *
RUDDY ET AL.: "Antitumorgenic evaluation of thalidomaide alone and in combination with cisplatin in DBA1/J mice", J. OF BIOMED. AND BIOTECH., vol. 2, 2002, pages 7 - 13, XP008101023 *
See also references of EP1606302A4 *
ZUGMAIER ET AL.: "Polysulfated heparanoids selectively inactivate heparin-binding angiogenesis factors", ANALS OF NY ACADEMY OF SCIENCES, vol. 886, 1999, pages 243 - 248, XP008100008 *

Also Published As

Publication number Publication date
CN1768075A (en) 2006-05-03
JP2007525414A (en) 2007-09-06
AU2004209428A1 (en) 2004-08-19
EP1606302A2 (en) 2005-12-21
CA2515000A1 (en) 2004-08-19
WO2004070008A2 (en) 2004-08-19
WO2004070008A8 (en) 2005-09-29
EP1606302A4 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2006091395A3 (en) Inhibitors of akt activity
WO2006063350A3 (en) Compositions and methods for treating conditions of the nail unit
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2006135627A3 (en) Inhibitors of akt activity
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2006031806A3 (en) 2-thiopyrimidinones as therapeutic agents
WO2006110638A3 (en) Inhibitors of akt activity
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2008011392A3 (en) Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2006086693A3 (en) Medical devices
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008049856A3 (en) Methods of treating pain using cdk inhibitors
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
WO2007041614A3 (en) Long acting vegf inhibitors and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 11193883

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 170013

Country of ref document: IL

Ref document number: 2006503176

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2515000

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004706977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004209428

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004209428

Country of ref document: AU

Date of ref document: 20040130

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004209428

Country of ref document: AU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 34/2004 UNDER (71,72) THE NAME SHOULD READ "WIENTJES, M. GUILLAUME"

WWE Wipo information: entry into national phase

Ref document number: 20048091217

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004706977

Country of ref document: EP